NCT00996346 arm group 1382e1c9d1f4ba93740d0deab61cad06 [clinicaltrials_resource:NCT00996346/arm-group/1382e1c9d1f4ba93740d0deab61cad06]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00996346 arm group 1382e1c9d1f4ba93740d0deab61cad06 [clinicaltrials_resource:NCT00996346/arm-group/1382e1c9d1f4ba93740d0deab61cad06]
Bio2RDF identifier
NCT00996346/arm-group/1382e1c9d1f4ba93740d0deab61cad06
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 82e1c9d1f4ba93740d0deab61cad06
description [clinicaltrials_vocabulary:description]
Irinotecan at 80 mg/m2 weekly x3; Level 3 Temsirolimus 25 mg weekly x3
identifier
clinicaltrials_resource:NCT00996346/arm-group/1382e1c9d1f4ba93740d0deab61cad06
title
NCT00996346 arm group 1382e1c9d1f4ba93740d0deab61cad06
@en
type
label
NCT00996346 arm group 1382e1c9 ...... 2e1c9d1f4ba93740d0deab61cad06]
@en